651 results on '"Stahl, Maximilian"'
Search Results
2. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
3. Mapping genotypes to chromatin accessibility profiles in single cells
4. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
5. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
6. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
7. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
8. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
9. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
10. Beyond HMAs: Novel Targets and Therapeutic Approaches
11. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis
12. TP53-mutated acute myeloid leukemia: how can we improve outcomes?
13. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
14. When to use which molecular prognostic scoring system in the management of patients with MDS?
15. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
16. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
17. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
18. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia
19. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
20. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
21. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
22. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
23. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells
24. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax
25. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
26. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.
27. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
28. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
29. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
30. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
31. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
32. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
33. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
34. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
35. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
36. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
37. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
38. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
39. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
40. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
41. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
42. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)
43. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
44. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
45. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
46. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)
47. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies
48. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
49. Selecting initial treatment of acute myeloid leukaemia in older adults
50. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.